
Clinuvel Pharmaceuticals Ltd
ASX:CUV

Intrinsic Value
The intrinsic value of one
CUV
stock under the Base Case scenario is
14.94
AUD.
Compared to the current market price of 11.59 AUD,
Clinuvel Pharmaceuticals Ltd
is
Undervalued by 22%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Clinuvel Pharmaceuticals Ltd
Fundamental Analysis

Revenue & Expenses Breakdown
Clinuvel Pharmaceuticals Ltd
Balance Sheet Decomposition
Clinuvel Pharmaceuticals Ltd
Current Assets | 227.6m |
Cash & Short-Term Investments | 198.2m |
Receivables | 16.3m |
Other Current Assets | 13.1m |
Non-Current Assets | 8.6m |
PP&E | 7.1m |
Intangibles | 185k |
Other Non-Current Assets | 1.3m |
Free Cash Flow Analysis
Clinuvel Pharmaceuticals Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Clinuvel Pharmaceuticals Ltd
Revenue
|
95.4m
AUD
|
Cost of Revenue
|
-3.2m
AUD
|
Gross Profit
|
92.2m
AUD
|
Operating Expenses
|
-36.9m
AUD
|
Operating Income
|
55.3m
AUD
|
Other Expenses
|
-16.5m
AUD
|
Net Income
|
38.8m
AUD
|
CUV Profitability Score
Profitability Due Diligence
Clinuvel Pharmaceuticals Ltd's profitability score is 76/100. The higher the profitability score, the more profitable the company is.

Score
Clinuvel Pharmaceuticals Ltd's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
CUV Solvency Score
Solvency Due Diligence
Clinuvel Pharmaceuticals Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Score
Clinuvel Pharmaceuticals Ltd's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CUV Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
CUV
is 26.47 AUD
with a low forecast of 15.15 AUD and a high forecast of 41.42 AUD.
Dividends
Current shareholder yield for CUV is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
CUV
stock under the Base Case scenario is
14.94
AUD.
Compared to the current market price of 11.59 AUD,
Clinuvel Pharmaceuticals Ltd
is
Undervalued by 22%.